Status:
ACTIVE_NOT_RECRUITING
ASCEND: A Study of Cardiovascular Events iN Diabetes
Lead Sponsor:
University of Oxford
Collaborating Sponsors:
British Heart Foundation
Bayer
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
40+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether 100mg daily aspirin versus placebo and/or supplementation with 1 gram daily omega-3 fatty acids or placebo prevents "serious vascular events" (i.e. no...
Detailed Description
The role of antiplatelet therapy (chiefly aspirin) for the secondary prevention of heart attacks and strokes is firmly established for many high-risk people with diagnosed arterial disease, and the pr...
Eligibility Criteria
Inclusion
- Males or females with type 1 or type 2 diabetes mellitus.
- Aged ≥ 40 years.
- No previous history of vascular disease.
- No clear contra-indication to aspirin.
- No other predominant life-threatening medical problem.
Exclusion
- Definite history of myocardial infarction, stroke or arterial revascularisation procedure.
- Currently prescribed aspirin, warfarin or any other blood thinning medication.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2037
Estimated Enrollment :
15480 Patients enrolled
Trial Details
Trial ID
NCT00135226
Start Date
March 1 2005
End Date
July 31 2037
Last Update
May 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Trial Service Unit, NDPH, University of Oxford
Oxford, United Kingdom, OX3 7LF